Oppenheimer Begins Coverage on Sensei Biotherapeutics (NASDAQ:FTH)

Oppenheimer initiated coverage on shares of Sensei Biotherapeutics (NASDAQ:FTH) in a note issued to investors on Tuesday,Benzinga reports. The firm set an “outperform” rating and a $60.00 price target on the stock. Oppenheimer’s price target suggests a potential upside of 105.20% from the stock’s previous close.

A number of other equities research analysts have also recently commented on the stock. BTIG Research reaffirmed a “buy” rating and issued a $55.00 target price on shares of Sensei Biotherapeutics in a report on Thursday, July 16th. Weiss Ratings assumed coverage on Sensei Biotherapeutics in a report on Wednesday, June 17th. They set a “sell (d-)” rating on the stock. Robert W. Baird initiated coverage on Sensei Biotherapeutics in a research report on Friday, June 26th. They issued an “outperform” rating and a $57.00 price target on the stock. Wall Street Zen downgraded Sensei Biotherapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Finally, HC Wainwright began coverage on Sensei Biotherapeutics in a research note on Monday, June 22nd. They issued a “buy” rating and a $60.00 target price on the stock. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $54.75.

Sensei Biotherapeutics Stock Performance

Shares of FTH opened at $29.24 on Tuesday. The company has a market cap of $39.18 million, a PE ratio of -0.20 and a beta of -0.26. Sensei Biotherapeutics has a 12-month low of $6.32 and a 12-month high of $37.90.

Sensei Biotherapeutics (NASDAQ:FTH) last released its quarterly earnings results on Friday, May 15th. The company reported ($131.45) EPS for the quarter. Analysts anticipate that Sensei Biotherapeutics will post -16.61 earnings per share for the current year.

Insider Activity

In other news, CEO Anand Kiran Parikh acquired 2,806 shares of Sensei Biotherapeutics stock in a transaction that occurred on Monday, June 22nd. The stock was purchased at an average price of $19.76 per share, for a total transaction of $55,446.56. Following the completion of the transaction, the chief executive officer directly owned 764,234 shares in the company, valued at approximately $15,101,263.84. This trade represents a 0.37% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder James Peyer sold 25,000 shares of Sensei Biotherapeutics stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $20.02, for a total value of $500,500.00. Following the completion of the sale, the insider directly owned 130,142 shares in the company, valued at $2,605,442.84. This represents a 16.11% decrease in their position. The SEC filing for this sale provides additional information. Insiders have bought a total of 49,494 shares of company stock valued at $1,188,822 over the last quarter. Corporate insiders own 7.00% of the company’s stock.

Institutional Trading of Sensei Biotherapeutics

Several hedge funds have recently modified their holdings of FTH. Renaissance Technologies LLC boosted its stake in shares of Sensei Biotherapeutics by 10.6% in the fourth quarter. Renaissance Technologies LLC now owns 11,516 shares of the company’s stock valued at $123,000 after buying an additional 1,100 shares in the last quarter. Bank of America Corp DE raised its position in Sensei Biotherapeutics by 10,692.5% in the first quarter. Bank of America Corp DE now owns 33,025 shares of the company’s stock worth $1,041,000 after acquiring an additional 32,719 shares in the last quarter. Stempoint Capital LP purchased a new position in Sensei Biotherapeutics in the first quarter worth $4,188,000. Finally, Vivo Capital LLC acquired a new stake in Sensei Biotherapeutics in the first quarter valued at $22,758,000. 10.50% of the stock is owned by institutional investors and hedge funds.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.